Ding Nik Sheng, Yip Wai Man, Choi C H, Saunders Brian, Thomas-Gibson Siwan, Arebi Naila, Humphries Adam, Hart Ailsa
Inflammatory Bowel Disease, St Mark's Hospital, London, UK Faculty of Medicine, Imperial College, London, UK
Inflammatory Bowel Disease, St Mark's Hospital, London, UK.
J Crohns Colitis. 2016 Oct;10(10):1172-8. doi: 10.1093/ecco-jcc/jjw072. Epub 2016 Mar 12.
To investigate the long-term efficacy of endoscopic dilatation of Crohn's anastomotic strictures and to identify risk and protective factors associated with the need for repeat dilatation or surgery.
A total of 54 patients who had endoscopic balloon dilatations for anastomotic Crohn's strictures between 2004 and 2009, with follow-up until June 2014, were identified from a single tertiary center. The primary end points were repeat dilatation or surgical resection, and the impact of radiology, medical therapy, and endoscopic data on these outcomes was analysed with Cox proportional hazards analysis.
A total of 151 dilatations were performed on patients with a median age of 52 years [interquartile range (IQR), 46-62 years]. The median duration from the first to the second dilatation was 6 years (IQR, 5-7 years). The median disease duration was 28 years (IQR, 19-32 years). At endoscopy, disease activity was reported in 50/54 (92%) cases, with a median Rutgeerts grading of i2 (range, i0-i4). A median of two (IQR 1-9) dilatations was required, with a time to repeat dilatation of 23 months (IQR 7.2-56.9). Escalation of medical therapy was adopted in 22/54 patients (41% of the study population). On multivariate analysis, only combination therapy (anti-TNFα and immunomodulator) was significantly associated with the (decreased) need for repeated dilatation [hazard ratio (HR) 0.23; 95% CI, 0.07-0.67; p = 0.01]. Anastomotic resections were performed in 10 (18%) patients, with a Rutgeerts score of i4 at initial endoscopic balloon dilatation being associated with this outcome (HR 4.55; 95% CI 1.08-19.29; p = 0.04) on multivariate analysis.
Endoscopic balloon dilatation of Crohn's anastomotic strictures is safe and effective in the long term. We demonstrate that active disease predicts for future surgery, while escalation of medical therapy may decrease the need for repeat dilatation.
研究克罗恩病吻合口狭窄内镜扩张的长期疗效,并确定与再次扩张或手术需求相关的风险因素和保护因素。
从一家三级中心识别出2004年至2009年间因吻合口克罗恩病狭窄接受内镜球囊扩张且随访至2014年6月的54例患者。主要终点为再次扩张或手术切除,采用Cox比例风险分析评估放射学、药物治疗和内镜数据对这些结局的影响。
共对中位年龄52岁(四分位间距[IQR],46 - 62岁)的患者进行了151次扩张。首次扩张至第二次扩张的中位时间为6年(IQR,5 - 7年)。中位病程为28年(IQR,19 - 32年)。内镜检查时,50/54(92%)例报告有疾病活动,中位鲁杰尔斯分级为i2(范围,i0 - i4)。中位需要进行两次(IQR 1 - 9)扩张,再次扩张时间为23个月(IQR 7.2 - 56.9)。22/54例患者(占研究人群的41%)采用了强化药物治疗。多因素分析显示,只有联合治疗(抗TNFα和免疫调节剂)与再次扩张需求(降低)显著相关[风险比(HR)0.23;95%置信区间,0.07 - 0.67;p = 0.01]。10例(18%)患者进行了吻合口切除术,多因素分析显示初始内镜球囊扩张时鲁杰尔斯评分为i4与该结局相关(HR 4.55;95%置信区间1.08 - 19.29;p = 0.04)。
克罗恩病吻合口狭窄的内镜球囊扩张长期来看是安全有效的。我们证明活动性疾病预示着未来需要手术,而强化药物治疗可能减少再次扩张的需求。